Adial Pharmaceuticals (ADIL) Competitors $2.08 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.04 -0.04 (-1.73%) As of 05/22/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADIL vs. QNCX, XCUR, TRAW, ZIVO, and LGVNShould you buy Adial Pharmaceuticals stock or one of its competitors? MarketBeat compares Adial Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adial Pharmaceuticals include Quince Therapeutics (QNCX), Exicure (XCUR), Traws Pharma (TRAW), ZIVO Bioscience (ZIVO), and Longeveron (LGVN). These companies are all part of the "pharmaceutical products" industry. ADIL vs. QNCXADIL vs. XCURADIL vs. TRAWADIL vs. ZIVOADIL vs. LGVNHow does Adial Pharmaceuticals compare to Quince Therapeutics?Adial Pharmaceuticals (NASDAQ:ADIL) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends. Is ADIL or QNCX more profitable? Adial Pharmaceuticals' return on equity of -162.82% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adial PharmaceuticalsN/A -162.82% -127.58% Quince Therapeutics N/A -372.88%-67.99% Does the media favor ADIL or QNCX? In the previous week, Adial Pharmaceuticals and Adial Pharmaceuticals both had 1 articles in the media. Quince Therapeutics' average media sentiment score of 0.08 beat Adial Pharmaceuticals' score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, ADIL or QNCX? Adial Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Which has better earnings and valuation, ADIL or QNCX? Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdial PharmaceuticalsN/AN/A-$7.98M-$7.98N/AQuince TherapeuticsN/AN/A-$83.98M-$10.62N/A Do institutionals & insiders have more ownership in ADIL or QNCX? 16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 20.3% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer ADIL or QNCX? Adial Pharmaceuticals presently has a consensus price target of $22.75, suggesting a potential upside of 993.75%. Quince Therapeutics has a consensus price target of $65.00, suggesting a potential upside of 5,809.09%. Given Quince Therapeutics' higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than Adial Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71 SummaryQuince Therapeutics beats Adial Pharmaceuticals on 7 of the 12 factors compared between the two stocks.How does Adial Pharmaceuticals compare to Exicure?Exicure (NASDAQ:XCUR) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment. Which has more risk & volatility, XCUR or ADIL? Exicure has a beta of 3.62, meaning that its stock price is 262% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Which has preferable valuation & earnings, XCUR or ADIL? Exicure has higher revenue and earnings than Adial Pharmaceuticals. Exicure is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K35.80-$4.95M-$0.77N/AAdial PharmaceuticalsN/AN/A-$7.98M-$7.98N/A Is XCUR or ADIL more profitable? Exicure's return on equity of -138.71% beat Adial Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -138.71% -62.76% Adial Pharmaceuticals N/A -162.82%-127.58% Do analysts prefer XCUR or ADIL? Adial Pharmaceuticals has a consensus target price of $22.75, indicating a potential upside of 993.75%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Adial Pharmaceuticals is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor XCUR or ADIL? In the previous week, Adial Pharmaceuticals had 1 more articles in the media than Exicure. MarketBeat recorded 1 mentions for Adial Pharmaceuticals and 0 mentions for Exicure. Exicure's average media sentiment score of 0.00 equaled Adial Pharmaceuticals'average media sentiment score. Company Overall Sentiment Exicure Neutral Adial Pharmaceuticals Neutral Do institutionals and insiders hold more shares of XCUR or ADIL? 42.8% of Exicure shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 52.8% of Exicure shares are owned by insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryExicure beats Adial Pharmaceuticals on 8 of the 13 factors compared between the two stocks.How does Adial Pharmaceuticals compare to Traws Pharma?Adial Pharmaceuticals (NASDAQ:ADIL) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Which has more volatility and risk, ADIL or TRAW? Adial Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Do insiders and institutionals have more ownership in ADIL or TRAW? 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 1.9% of Adial Pharmaceuticals shares are owned by insiders. Comparatively, 14.0% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor ADIL or TRAW? In the previous week, Traws Pharma had 10 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 11 mentions for Traws Pharma and 1 mentions for Adial Pharmaceuticals. Traws Pharma's average media sentiment score of 0.56 beat Adial Pharmaceuticals' score of 0.00 indicating that Traws Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ADIL or TRAW? Adial Pharmaceuticals presently has a consensus price target of $22.75, suggesting a potential upside of 993.75%. Traws Pharma has a consensus price target of $8.00, suggesting a potential upside of 436.91%. Given Adial Pharmaceuticals' higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Traws Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Is ADIL or TRAW more profitable? Adial Pharmaceuticals' return on equity of -162.82% beat Traws Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Adial PharmaceuticalsN/A -162.82% -127.58% Traws Pharma N/A -913.18%-133.88% Which has preferable earnings and valuation, ADIL or TRAW? Traws Pharma has higher revenue and earnings than Adial Pharmaceuticals. Traws Pharma is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdial PharmaceuticalsN/AN/A-$7.98M-$7.98N/ATraws Pharma$2.79M5.43$9.17M-$1.69N/A SummaryTraws Pharma beats Adial Pharmaceuticals on 9 of the 14 factors compared between the two stocks.How does Adial Pharmaceuticals compare to ZIVO Bioscience?Adial Pharmaceuticals (NASDAQ:ADIL) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations. Do institutionals and insiders have more ownership in ADIL or ZIVO? 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 1.9% of Adial Pharmaceuticals shares are owned by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, ADIL or ZIVO? ZIVO Bioscience has higher revenue and earnings than Adial Pharmaceuticals. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdial PharmaceuticalsN/AN/A-$7.98M-$7.98N/AZIVO Bioscience$15.85K1,075.20-$7.78M-$1.71N/A Does the media favor ADIL or ZIVO? In the previous week, Adial Pharmaceuticals had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 1 mentions for Adial Pharmaceuticals and 0 mentions for ZIVO Bioscience. Adial Pharmaceuticals' average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score. Company Overall Sentiment Adial Pharmaceuticals Neutral ZIVO Bioscience Neutral Which has more volatility and risk, ADIL or ZIVO? Adial Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market. Is ADIL or ZIVO more profitable? ZIVO Bioscience's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Adial PharmaceuticalsN/A -162.82% -127.58% ZIVO Bioscience N/A N/A -2,240.92% Do analysts rate ADIL or ZIVO? Adial Pharmaceuticals presently has a consensus price target of $22.75, indicating a potential upside of 993.75%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Adial Pharmaceuticals is more favorable than ZIVO Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAdial Pharmaceuticals beats ZIVO Bioscience on 8 of the 13 factors compared between the two stocks.How does Adial Pharmaceuticals compare to Longeveron?Adial Pharmaceuticals (NASDAQ:ADIL) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Do insiders and institutionals hold more shares of ADIL or LGVN? 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 1.9% of Adial Pharmaceuticals shares are owned by company insiders. Comparatively, 11.2% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, ADIL or LGVN? Adial Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.31, indicating that its stock price is 131% less volatile than the broader market. Does the media prefer ADIL or LGVN? In the previous week, Longeveron had 13 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 14 mentions for Longeveron and 1 mentions for Adial Pharmaceuticals. Longeveron's average media sentiment score of 0.93 beat Adial Pharmaceuticals' score of 0.00 indicating that Longeveron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ADIL or LGVN? Adial Pharmaceuticals currently has a consensus target price of $22.75, suggesting a potential upside of 993.75%. Longeveron has a consensus target price of $5.50, suggesting a potential upside of 570.57%. Given Adial Pharmaceuticals' higher probable upside, research analysts clearly believe Adial Pharmaceuticals is more favorable than Longeveron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has stronger earnings and valuation, ADIL or LGVN? Adial Pharmaceuticals has higher earnings, but lower revenue than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdial PharmaceuticalsN/AN/A-$7.98M-$7.98N/ALongeveron$1.20M15.91-$22.70M-$1.13N/A Is ADIL or LGVN more profitable? Adial Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Adial Pharmaceuticals' return on equity of -162.82% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets Adial PharmaceuticalsN/A -162.82% -127.58% Longeveron -1,844.49%-202.41%-140.67% SummaryAdial Pharmaceuticals beats Longeveron on 8 of the 15 factors compared between the two stocks. Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADIL vs. The Competition ExportMetricAdial PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.46M$477.13M$6.45B$12.34BDividend YieldN/A3.87%2.76%5.28%P/E Ratio-0.263.8121.2225.65Price / SalesN/A7,288.62553.9286.28Price / CashN/A13.1343.4956.67Price / Book1.2084.7810.377.14Net Income-$7.98M-$96.07M$3.57B$335.98M7 Day Performance29.19%1.01%6.01%3.56%1 Month Performance31.65%0.50%3.52%2.54%1 Year Performance-87.94%64.34%34.13%35.05% Adial Pharmaceuticals Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADILAdial Pharmaceuticals1.5311 of 5 stars$2.08flat$22.75+993.8%-87.9%$4.46MN/AN/A20Gap UpQNCXQuince Therapeutics2.1431 of 5 stars$1.08+8.6%$65.00+5,918.5%-90.1%$17.61MN/AN/A60Gap DownXCURExicure0.5379 of 5 stars$2.76-9.8%N/A-72.0%$17.59M$500KN/A50TRAWTraws Pharma3.2056 of 5 stars$1.70-3.6%$8.00+371.7%+13.7%$17.24M$2.79MN/A17Analyst RevisionZIVOZIVO BioscienceN/A$4.06flatN/AN/A$16.86M$15.85KN/A10Gap Up Related Companies and Tools Related Companies Quince Therapeutics Alternatives Exicure Alternatives Traws Pharma Alternatives ZIVO Bioscience Alternatives Longeveron Alternatives Passage Bio Alternatives NLS Pharmaceutics Alternatives Mymd Pharmaceuticals Alternatives Natural Alternatives International Alternatives Applied Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADIL) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
